TuHURA CEO to Present at H.C. Wainwright Conference Amid Key Clinical Trials
Event summary
- TuHURA Biosciences CEO James A. Bianco to present at H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026.
- Company is enrolling patients in Phase 3 trial for IFx-2.0 as adjunctive therapy to Keytruda for advanced Merkel Cell Carcinoma.
- TBS-2025, a VISTA inhibiting mAb, moving into Phase 1b trial for mutNPM1 r/r AML.
- TuHURA developing first-in-class bi-specific ADCs targeting MDSCs to prevent T cell exhaustion.
The big picture
TuHURA's presentation comes as the company advances multiple clinical trials aimed at overcoming resistance to cancer immunotherapy, a critical challenge in the field. The focus on both primary and acquired resistance positions TuHURA at the forefront of next-generation immuno-oncology treatments, with potential implications for patient outcomes and market dynamics.
What we're watching
- Trial Momentum
- The pace at which TuHURA completes enrollment in its Phase 3 trial for IFx-2.0 will determine its regulatory timeline.
- Competitive Positioning
- Whether TuHURA can differentiate its resistance-overcoming therapies in a crowded immuno-oncology space.
- Technology Validation
- The efficacy of TuHURA's Delta Opioid Receptor technology in preventing acquired resistance.